Report error Found 205 with Last Name = 'weihofen' and Initial = 'wa'
Affinity DataIC50: 0.400nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
Affinity DataIC50: <0.700nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
Affinity DataIC50: <0.700nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
TargetNicotinamide phosphoribosyltransferase(Human)
Novartis Institute For Biomedical Research
Curated by ChEMBL
Novartis Institute For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: <1nMAssay Description:Inhibition of full length recombinant human NAMPT using N15-NAM as substrate preincubated for 15 mins followed by substrate addition and measured aft...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
TargetNicotinamide phosphoribosyltransferase(Human)
Novartis Institute For Biomedical Research
Curated by ChEMBL
Novartis Institute For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 2.70nMAssay Description:Inhibition of full length recombinant human NAMPT using N15-NAM as substrate preincubated for 15 mins followed by substrate addition and measured aft...More data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
Affinity DataIC50: 7nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:Inhibition of human complement FD by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 9nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
Affinity DataIC50: 9nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:Inhibition of N-terminal human plasma F11a catalytic domain expressed in Escherichia coli strain BL21(DE3) using D-Leu-Pro-Arg*Rh110-D-Pro as substra...More data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:Inhibition of N-terminal human plasma F11a catalytic domain expressed in Escherichia coli strain BL21(DE3) using D-Leu-Pro-Arg*Rh110-D-Pro as substra...More data for this Ligand-Target Pair
Affinity DataIC50: 11nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
Affinity DataIC50: 12nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
Affinity DataIC50: 15nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Human)
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 16nMAssay Description:Inhibition of human urokinase using fluorescent peptide as substrate by florescence assayMore data for this Ligand-Target Pair
Affinity DataIC50: 16nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
Affinity DataIC50: 17nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Human)
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 20nMAssay Description:Inhibition of human uPA using fluorescent peptide as substrate by florescence assayMore data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Human)
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 20nMAssay Description:Inhibition of human uPA using fluorescent peptide as substrate by florescence assayMore data for this Ligand-Target Pair
Affinity DataIC50: 21nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
Affinity DataIC50: 25nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
Affinity DataIC50: 30nMAssay Description:Inhibition of human F9a using fluorescent peptide as substrate by florescence assayMore data for this Ligand-Target Pair
Affinity DataIC50: 30nMAssay Description:Inhibition of human thrombin using fluorescent peptide as substrate by florescence assayMore data for this Ligand-Target Pair
Affinity DataIC50: 40nMAssay Description:Inhibition of human complement FD by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 40nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
Affinity DataIC50: 40nMAssay Description:Inhibition of human F9a using fluorescent peptide as substrate by florescence assayMore data for this Ligand-Target Pair
Affinity DataIC50: 40nMAssay Description:Inhibition of human complement FD by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 41nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
Affinity DataIC50: 45nMAssay Description:Inhibition of N-terminal human plasma F11a catalytic domain expressed in Escherichia coli strain BL21(DE3) using D-Leu-Pro-Arg*Rh110-D-Pro as substra...More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Human)
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 47nMAssay Description:Inhibition of human uPA using fluorescent peptide as substrate by florescence assayMore data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Human)
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 47nMAssay Description:Inhibition of human urokinase using fluorescent peptide as substrate by florescence assayMore data for this Ligand-Target Pair
Affinity DataIC50: 50nMAssay Description:Inhibition of human thrombin using fluorescent peptide as substrate by florescence assayMore data for this Ligand-Target Pair
Affinity DataIC50: 50nMAssay Description:Inhibition of N-terminal human plasma F11a catalytic domain expressed in Escherichia coli strain BL21(DE3) using D-Leu-Pro-Arg*Rh110-D-Pro as substra...More data for this Ligand-Target Pair
Affinity DataIC50: 50nMAssay Description:Inhibition of human complement FD by TR-FRET assayMore data for this Ligand-Target Pair
TargetTissue-type plasminogen activator(Human)
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 50nMAssay Description:Inhibition of human tPa using fluorescent peptide as substrate by florescence assayMore data for this Ligand-Target Pair